Format

Send to

Choose Destination
Sci Signal. 2009 Nov 24;2(98):ra75. doi: 10.1126/scisignal.2000559.

mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells.

Author information

1
1Division of Immunotherapy, Department of Surgery, University of Michigan School of Medicine and Comprehensive Cancer Center, Ann Arbor, MI 48109, USA.

Abstract

Age-related declines in hematopoietic stem cell (HSC) function may contribute to anemia, poor response to vaccination, and tumorigenesis. Here, we show that mammalian target of rapamycin (mTOR) activity is increased in HSCs from old mice compared to those from young mice. mTOR activation through conditional deletion of Tsc1 in the HSCs of young mice mimicked the phenotype of HSCs from aged mice in various ways. These included increased abundance of the messenger RNA encoding the CDK inhibitors p16(Ink4a), p19(Arf), and p21(Cip1); a relative decrease in lymphopoiesis; and impaired capacity to reconstitute the hematopoietic system. In old mice, rapamycin increased life span, restored the self-renewal and hematopoiesis of HSCs, and enabled effective vaccination against a lethal challenge with influenza virus. Together, our data implicate mTOR signaling in HSC aging and show the potential of mTOR inhibitors for restoring hematopoiesis in the elderly.

PMID:
19934433
PMCID:
PMC4020596
DOI:
10.1126/scisignal.2000559
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center